Phase 2Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus
- Sponsor
- Hanmi Pharmaceutical Company Limited (Industry)
- Enrollment
- 180 planned
- Conditions
- Type 2 Diabetes Mellitus; T2DM
- Interventions
- HM15275; Placebo of HM15275
- Ages
- adults, older adults
- Registry
- NCT07527650
Full record on ClinicalTrials.gov
From the registry
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Primary outcomes
- Change in Glycated Hemoglobin (HbA1c)
History
Primary completion expected
Last registry update
Started
Registered